Cetirizine is safe and appropriate for a 6-month-old infant
Cetirizine can be used in infants as young as 6 months of age and has been shown to have an excellent safety profile in this age group. 1
Evidence Supporting Use in Infants
The 2008 rhinitis practice parameter guidelines explicitly distinguish cetirizine from older over-the-counter antihistamines, stating that "second-generation antihistamines such as cetirizine, desloratadine, fexofenadine, levocetirizine, and loratadine when used in young children have been shown to be well tolerated and to have a very good safety profile" 1. This is in stark contrast to first-generation antihistamines and decongestants, which should be avoided in children under 6 years due to safety concerns including fatalities.
A prospective, randomized, double-blind, placebo-controlled study specifically evaluated cetirizine safety in infants aged 6-11 months 2. This landmark study—the first of its kind for any H1-antihistamine in infants—used a dose of 0.25 mg/kg twice daily (mean daily dose 4.5 mg) for one week and found:
- No differences in adverse events between cetirizine and placebo groups
- A trend toward fewer sleep disturbances in the cetirizine group
- No cardiac effects (no QT prolongation)
- Overall excellent tolerability
Dosing Recommendations
For infants 6-11 months old:
- 0.25 mg/kg twice daily is the evidence-based dose 2, 3
- This typically translates to approximately 2.5 mg twice daily for most infants in this age range
Important Caveats
Mild sedation is possible: Cetirizine may cause drowsiness even at recommended doses, unlike some other second-generation antihistamines (fexofenadine, loratadine, desloratadine) 1. However, in the infant safety study, sedation was not more common than placebo 2.
Renal function: Cetirizine is predominantly eliminated by the kidneys. In infants with renal impairment, dose adjustment would be necessary 4.
FDA labeling: While the FDA drug label indicates "6 yrs & older" for over-the-counter formulations 5, this reflects OTC marketing restrictions rather than safety data. The prescription use in infants 6 months and older is supported by clinical evidence and is licensed in the USA for this age group 6.
Clinical Context
This recommendation applies to allergic conditions (allergic rhinitis, urticaria) where antihistamine therapy is indicated. The safety profile established in controlled studies supports its use when clinically appropriate, with proper weight-based dosing and monitoring for the expected mild sedative effects.